Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer

Gynecologic Oncology

Volumn 92, Issue 3, 2004, Pages 927-935

  Seo, Sang Soo ^a   Song, Yong Sang ^a,b   Kang, Dae Hee ^b   Park, In Ae ^b   Bang, Yung Jue ^b   Kang, Soon Beom ^b   Lee, Hyo Pyo ^b  

^a National Cancer Center   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

COX 2; Epithelial ovarian cancer; p53; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOOXYGENASE 2; MOLECULAR MARKER; PARAFFIN; PROTEIN P53; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ARTICLE; ASCITES; ASSOCIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; EPITHELIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TISSUE TYPES;

EID: 1342321831     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.11.055     Document Type: Article

References (56)

1. Huober J., Meyer A., Wagner U., Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J. Cancer Res. Clin. Oncol. 128:2002;153-160.
2. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38:1998;97-120.
3. Ness R.B., Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J. Natl. Cancer Inst. 91:1999;1459-1467.
4. Newhouse M.L., Berry G., Wagner J.C. Mortality of factory workers in east London 1933-80. Br. J. Ind. Med. 42:1985;4-11.
5. Cramer D.W., Welch W.R., Scully R.E., Wojciechowski C.A. Ovarian cancer and talc: a case-control study. Cancer. 50:1982;372-376.
6. Harlow B.L., Cramer D.W., Bell D.A., Welch W.R. Perineal exposure to talc and ovarian cancer risk. Obstet. Gynecol. 80:1992;19-26.
7. Shu X.O., Brinton L.A., Gao Y.T., Yuan J.M. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res. 49:1989;3670-3674.
8. Risch H.A., Howe G.R. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol. Biomark. Prev. 4:1995;447-451.
9. Dreher D., Junod A.F. Role of oxygen free radicals in cancer development. Eur. J. Cancer. 32:1996;30-38.
10. Gallo O., Franchi A., Magnelli L., Sardi I., Vannacci A., Boddi V.et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia. 3:2001;53-61.
11. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M.et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 7:2001;861-867.
12. Plevris J.N., Heading R.C. Present medical management of Barrett's oesophagus. Dig. Liver Dis. 33:2001;278-283.
13. Kashiwagi H., Spigelman A.D. Gastroduodenal lesions in familial adenomatous polyposis. Surg. Today. 30:2000;675-682.
14. Watkins D.N., Lenzo J.C., Segal A., Garlepp M.J., Thompson P.J. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur. Respir. J. 14:1999;412-418.
15. Sakuma K., Fujimori T., Hirabayashi K., Terano A. Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer. J. Gastroenterol. 34:1999;189-194.
16. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:1998;4997-5001.
17. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 18:1999;7908-7916.
18. Ryu H.S., Chang K.H., Yang H.W., Kim M.S., Kwon H.C., Oh K.S. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol. Oncol. 76:2000;320-325.
19. Chen W.S., Wei S.J., Liu J.M., Hsiao M., Kou-Lin J., Yang W.K. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int. J. Cancer. 91:2001;894-899.
20. Ohno R., Yoshinaga K., Fujita T., Hasegawa K., Iseki H., Tsunozaki H.et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer. 91:2001;1876-1881.
21. Shirahama T., Arima J., Akiba S., Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer. 92:2001;188-193.
22. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M.et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 7:2001;861-867.
23. Kawamoto T., Shoda J., Asano T., Ueda T., Furukawa M., Koike N.et al. Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int. J. Cancer. 98:2002;427-434.
24. Gaffney D.K., Holden J., Davis M., Zempolich K., Murphy K.J., Dodson M. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 49:2001;1213-1217.
25. Ferrandina G., Ranelletti F.O., Lauriola L., Fanfani F., Legge F., Mottolese M.et al. Cyclooxygenase-2 (COX-2), Epidermal Growth Factor Receptor (EGFR), and Her-2/neu Expression in Ovarian Cancer. Gynecol. Oncol. 85:2002;305-310.
26. Ratnasinghe D., Daschner P.J., Anver M.R., Kasprzak B.H., Taylor P.R., Yeh G.C.et al. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res. 21:2001;2141-2147.
27. Mills G.B. Mechanisms underlying chemoprevention of ovarian cancer. Clin. Cancer Res. 8:2002;7-10.
28. Meier C.R., Schmitz S., Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy. 22:2002;303-309.
29. Vainio H. Is COX-2 inhibition a panacea for cancer prevention? Int. J. Cancer. 94:2001;613-614.
30. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94:2002;252-266.
31. Blanke C.D. Celecoxib with chemotherapy in colorectal cancer. Oncology (Huntingt). 16:2002;17-21.
32. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24:2003;96-102.
33. Dore M., Cote L.C., Mitchell A., Sirois J. Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J. Histochem. Cytochem. 46:1998;77-84.
34. Matsumoto Y., Ishiko O., Deguchi M., Nakagawa E., Ogita S. Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int. J. Mol. Med. 8:2001;31-36.
35. Klimp A.H., Hollema H., Kempinga C., van der Zee A.G., de Vries E.G., Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res. 61:2001;7305-7309.
36. Shigemasa K., Tian X., Gu L., Shiroyama Y., Nagai N., Ohama K. Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int. J. Oncol. 22:2003;99-105.
37. Denkert C., Kobel M., Pest S., Koch I., Berger S., Schwabe M.et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am. J. Pathol. 160:2002;893-903.
38. Werness B.A., Freedman A.N., Piver M.S., Romero-Gutierrez M., Petrow E. Prognostic significance of p53 and p21(waf1/cip1) immunoreactivity in epithelial cancers of the ovary. Gynecol. Oncol. 75:1999;413-418.
39. Elbendary A.A., Cirisano F.D., Evans A.C. Jr., Davis P.L., Iglehart J.D., Marks J.R.et al. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin. Cancer Res. 2:1996;1571-1575.
40. Geisler H.E., Geisler J.P., Miller G.A., Geisler M.J., Wiemann M.C., Zhou Z.et al. p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone. Cancer. 92:2001;781-786.
41. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., Sampat A., Dannenberg A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274:1999;10911-10915.
42. Brustmann H., Naude S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol. Oncol. 84:2002;47-52.
43. Ristimaki A., Honkanen N., Jankala H., Sipponen P., Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1997;1276-1280.
44. Annual Report of Gynecologic Cancer Registry Program in Korean for 1999 (Jan. 1, 1000-Dec. 31, 1999). Kor J Obstet Gynecol 2002;45:1665-99.
45. McGuire V., Jesser C.A., Whittemore A.S. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol. Oncol. 84:2002;399-403.
46. Pieretti M., Hopenhayn-Rich C., Khattar N.H., Cao Y., Huang B., Tucker T.C. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest. 20:2002;11-23.
47. Levesque M.A., Katsaros D., Massobrio M., Genta F., Yu H., Richiardi G. et al. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Clin. Cancer Res. 6:2000;3260-3270.
48. Reles A., Wen W.H., Schmider A., Gee C., Runnebaum I.B., Kilian U.et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. 7:2001;2984-2997.
49. Rajnakova A., Moochhala S., Goh P.M., Ngoi S. Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett. 172:2001;177-185.
50. Leung W.K., To K.F., Ng Y.P., Lee T.L., Lau J.Y., Chan F.K.et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br. J. Cancer. 84:2001;335-339.
51. Biramijamal F., Allameh A., Mirbod P., Groene H.J., Koomagi R., Hollstein M. Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran. Cancer Res. 61:2001;3119-3123.
52. Han J.A., Kim J.I., Ongusaha P.P., Hwang D.H., Ballou L.R., Mahale A.et al. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J. 21:2002;5635-5644.
53. Ogawa S., Kaku T., Kobayashi H., Hirakawa T., Ohishi Y., Kinukawa N.et al. Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett. 176:2002;111-118.
54. Skirnisdottir I., Sorbe B., Karlsson M., Seidal T. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma. Int. J. Oncol. 19:2001;1295-1302.
55. Kigawa J., Sato S., Shimada M., Takahashi M., Itamochi H., Kanamori Y.et al. p53 gene status and chemosensitivity in ovarian cancer. Hum. Cell. 14:2001;165-171.
56. Wang J., Luo F., Lu J.J., Chen P.K., Liu P., Zheng W. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int. J. Cancer. 97:2002;163-167.